Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 58%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is expected to see strong growth in their biopharma business and their Reveal test, but increased competition and potential marketing expenses could hinder their growth. However, the company is taking steps to enhance their offerings and expand into new markets, such as the inclusion of their Shield CRC test in industry guidelines and potential payor mandates. Despite potential challenges, analysts believe GH has a positive outlook and could see their shares trading at a higher price in the future.

Bears say

Guardant Health is a leader in the liquid-based testing market, but their competitors are catching up and could impact their future market share. Additionally, the company's high reliance on government regulations and reimbursements could impact their future growth and profitability. The recent failure of a clinical trial for one of their products and potential challenges related to FDA regulations also pose risks to the company's success.

GH has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 58% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 19 analysts, GH has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $119.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $119.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.